First-in-human study to investigate the skin tolerability of micro-projection array patches coated with inactivated split influenza virus haemagglutinin (HA) from A/Singapore/GP1908/2015 (A/Michigan/45/2015(H1N1)-like) vaccine in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2019
Price : $35 *
At a glance
- Drugs Influenza-A-virus-H1N1-vaccines-Vaxxas (Primary) ; Influenza vaccine quadrivalent Seqirus
- Indications Influenza virus infections
- Focus Adverse reactions; First in man
- Sponsors Vaxxas
- 24 Jul 2019 Status changed from recruiting to completed.
- 20 Feb 2018 Status changed from not yet recruiting to recruiting.
- 02 Feb 2018 New trial record